Seattle Genetics receives anti-CD30 patent claims

By Elaine Rigoli

Tampa, Fla., April 11 - Seattle Genetics, Inc. has received a notice of allowance from the U.S. Patent and Trademark Office for a patent entitled "Recombinant Anti-CD30 Antibodies and Uses Thereof."

The issued claims cover methods of using certain anti-CD30 antibodies for the treatment of Hodgkin's disease, both as a single agent and in combination with other therapies, according to a news release.

The company said it currently has two anti-CD30 product candidates in development: SGN-30, a genetically engineered antibody in phase 2 clinical development for Hodgkin's disease and T-cell lymphomas, and SGN-35, an antibody-drug conjugate planned to enter clinical trials during 2006.

SGN-30 is a genetically engineered antibody that has shown objective anti-tumor activity, including complete and partial responses, in ongoing phase 2 clinical trials of systemic and cutaneous anaplastic large cell lymphoma, the release said.

Headquartered in Bothell, Wash., Seattle Genetics is a biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer and immunologic diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.